Kairos Pharma Ltd
KAPA0.848USD
+0.073+9.47%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
17.66MMarket Cap
LossP/E TTM
More Details of Kairos Pharma Ltd Company
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
Kairos Pharma Ltd Info
Ticker SymbolKAPA
Company nameKairos Pharma Ltd
IPO dateSep 16, 2024
CEOYu (John S)
Number of employees1
Security typeOrdinary Share
Fiscal year-endSep 16
Address2355 Westwood Blvd. #139
CityLOS ANGELES
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code90064
Phone18184045541
Websitehttps://kairospharma.com
Ticker SymbolKAPA
IPO dateSep 16, 2024
CEOYu (John S)
Company Executives of Kairos Pharma Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
5.53M
+3.57%
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
49.20K
+63.36%
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Independent Director
Independent Director
29.08K
+190.84%
Mr. Douglas W. (Doug) Samuelson, CPA
Mr. Douglas W. (Doug) Samuelson, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Neil Bhowmick, Ph.D.
Dr. Neil Bhowmick, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ramachandran Murali, Ph.D.
Dr. Ramachandran Murali, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Hyun W. Bae, M.D.
Dr. Hyun W. Bae, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
5.53M
+3.57%
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
49.20K
+63.36%
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Independent Director
Independent Director
29.08K
+190.84%
Mr. Douglas W. (Doug) Samuelson, CPA
Mr. Douglas W. (Doug) Samuelson, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Neil Bhowmick, Ph.D.
Dr. Neil Bhowmick, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ramachandran Murali, Ph.D.
Dr. Ramachandran Murali, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 17
Updated: Wed, Dec 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Yu (John S)
26.57%
Technomedics Management and Systems, Inc
5.64%
Bhowmick (Neil Ph.D.)
5.43%
Murali (Ramachandran Ph.D.)
1.39%
Samuelson (Doug)
1.24%
Other
59.74%
Shareholders
Shareholders
Proportion
Yu (John S)
26.57%
Technomedics Management and Systems, Inc
5.64%
Bhowmick (Neil Ph.D.)
5.43%
Murali (Ramachandran Ph.D.)
1.39%
Samuelson (Doug)
1.24%
Other
59.74%
Shareholder Types
Shareholders
Proportion
Individual Investor
35.22%
Corporation
5.64%
Investment Advisor
1.09%
Investment Advisor/Hedge Fund
0.54%
Hedge Fund
0.44%
Venture Capital
0.06%
Other
57.01%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
17
350.58K
1.69%
-1.62M
2025Q2
19
9.54M
54.94%
+1.17M
2025Q1
19
10.48M
74.82%
+2.27M
2024Q4
13
9.19M
70.90%
+3.62M
2024Q3
9
8.91M
68.86%
+8.91M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Yu (John S)
5.34M
25.75%
--
--
Jul 28, 2025
Technomedics Management and Systems, Inc
1.17M
5.66%
--
--
Jul 28, 2025
Bhowmick (Neil Ph.D.)
1.13M
5.45%
--
--
Jul 28, 2025
Murali (Ramachandran Ph.D.)
137.52K
0.66%
--
--
Jul 28, 2025
Samuelson (Doug)
104.89K
0.51%
--
--
Jul 28, 2025
The Vanguard Group, Inc.
10.72K
0.05%
--
--
Aug 31, 2025
Two Sigma Investments, LP
13.55K
0.07%
+13.55K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
21.80K
0.11%
+1.37K
+6.71%
Jun 30, 2025
Singhvi (Rahul)
30.12K
0.15%
+30.12K
--
Dec 10, 2024
Bae (Hyun W. M.D.)
44.29K
0.21%
--
--
Jul 28, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Kairos Pharma Ltd?
The top five shareholders of Kairos Pharma Ltd are:
Yu (John S) holds 5.34M shares, accounting for 25.75% of the total shares.
Technomedics Management and Systems, Inc holds 1.17M shares, accounting for 5.66% of the total shares.
Bhowmick (Neil Ph.D.) holds 1.13M shares, accounting for 5.45% of the total shares.
Murali (Ramachandran Ph.D.) holds 137.52K shares, accounting for 0.66% of the total shares.
Samuelson (Doug) holds 104.89K shares, accounting for 0.51% of the total shares.
Yu (John S) holds 5.34M shares, accounting for 25.75% of the total shares.
Technomedics Management and Systems, Inc holds 1.17M shares, accounting for 5.66% of the total shares.
Bhowmick (Neil Ph.D.) holds 1.13M shares, accounting for 5.45% of the total shares.
Murali (Ramachandran Ph.D.) holds 137.52K shares, accounting for 0.66% of the total shares.
Samuelson (Doug) holds 104.89K shares, accounting for 0.51% of the total shares.
What are the top three shareholder types of Kairos Pharma Ltd?
The top three shareholder types of Kairos Pharma Ltd are:
Yu (John S)
Technomedics Management and Systems, Inc
Bhowmick (Neil Ph.D.)
Yu (John S)
Technomedics Management and Systems, Inc
Bhowmick (Neil Ph.D.)
How many institutions hold shares of Kairos Pharma Ltd (KAPA)?
As of 2025Q3, 17 institutions hold shares of Kairos Pharma Ltd, with a combined market value of approximately 350.58K, accounting for 1.69% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -53.25%.
What is the biggest source of revenue for Kairos Pharma Ltd?
In --, the -- business generated the highest revenue for Kairos Pharma Ltd, amounting to -- and accounting for --% of total revenue.
